{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:38:16Z","timestamp":1792291096871,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007698.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000}}],"reference-count":93,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007698.pub3","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T12:02:25Z","timestamp":1445860945000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Oral budesonide for induction of remission in ulcerative colitis"],"prefix":"10.1002","volume":"2015","author":[{"given":"Mary E","family":"Sherlock","sequence":"first","affiliation":[{"name":"McMaster Children's Hospital; Division of Gastroenterology & Nutrition; Hamilton Health Sciences 1280 Main Street West Hamilton ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Robarts Research Institute; Robarts Clinical Trials; P.O. Box 5015 100 Perth Drive London ON Canada N6A 5K8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Griffiths","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children; Division of Gastroenterology, Hepatology & Nutrition; 555 University Ave. Toronto ON Canada M5G 1X8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital; Department of Medicine, Division of Gastroenterology; Room 445, 600 University Avenue Toronto ON Canada M5G 1X5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"University of Calgary; Department of Medicine; TRW Building Rm 6D18 3280 Hospital Drive NW Calgary AB Canada T2N 4Z6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007698.pub3-BIB0001|cit1","first-page":"A505","article-title":"Safety and efficacy of a novel extended release budesonide formulation in patients with active left-sided ulcerative colitis","volume":"132","author":"D'Haens","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.crohns.2009.09.007","article-title":"Clinical trial: Preliminary efficacy and safety study of a new budesonide-MMX\u00ae 9 mg extended-release tablets in patients with active left-sided ulcerative colitis","volume":"4","author":"D'Haens","year":"2010","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2010.11.006","article-title":"3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial","volume":"5","author":"Gross","year":"2011","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0004|cit4","first-page":"A15","article-title":"Efficacy and tolerability of a once daily treatment with budesonide capsules versus mesalamine granules for the treatment of active ulcerative colitis: A randomized, double-blind, double-dummy, multicenter study","volume":"136","author":"Gross","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1053\/gast.1996.v110.pm8964395","article-title":"Oral budesonide versus prednisone in patients with active extensive and left-sided ulcerative colitis","volume":"110","author":"L\u00f6fberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0006|cit6","first-page":"S1","article-title":"Budesonide MMX 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-asas","volume":"20","author":"Rubin","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0007|cit7","first-page":"S124","article-title":"Budesonide Mxx 9mg for the induction of remission of mild-to-moderate ulcerative colitis (UC): Data from a multicenter, randomized, double-blind placebo-controlled study in North America and India","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007698.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily Budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE 1 study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0009|cit9","first-page":"S65","article-title":"Budesonide-MMx 9 mg for induction of remission of mild-to-moderate ulcerative colitis (UC): Data from a multicenter, randomized, double-blind placebo-controlled study in the Europe, Russia, Israel and Australia","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active mild-to-moderate ulcerative colitis: results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.MIB.0000192323.82426.83","article-title":"Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice","volume":"12","author":"Chopra","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD007698.pub3-BIB0012|cit12","first-page":"OP262","article-title":"Budesonide MMX\u00ae efficacy is independent of previous mesalazine exposure in ulcerative colitis: pooled analysis of CORE I and CORE II","volume":"1","author":"Danese","year":"2013","journal-title":"United European Gastroenterology Journal"},{"issue":"11","key":"10.1002\/14651858.CD007698.pub3-BIB0013|cit13","first-page":"802","article-title":"Advances in the topical steroid treatment of inflammatory bowel disease","volume":"87","author":"D\u00edas Blasco","year":"1995","journal-title":"Revista Espa\u00f1ola de Enfermedades Digestivas"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1053\/gast.1996.v110.agast962000","article-title":"Budesonide therapy for ulcerative colitis: a topical tale","volume":"110","author":"Feagan","year":"1996","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.addr.2004.08.009","article-title":"Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide","volume":"57","author":"Fedorak","year":"2005","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"10","key":"10.1002\/14651858.CD007698.pub3-BIB0016|cit16","first-page":"525","article-title":"Budesonide and inflammatory bowel disease","volume":"22","author":"Gomoll\u00f3n","year":"1999","journal-title":"Gastroenterolog\u00eda y Hepatolog\u00eda"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.1997.00263.x","article-title":"Oral budesonide therapy for steroid-dependent ulcerative colitis","volume":"11","author":"Keller","year":"1997","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD007698.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1358\/dot.2004.40.7.850477","article-title":"Evaluation of oral budesonide in the treatment of active distal ulcerative colitis","volume":"40","author":"Kolkman","year":"2004","journal-title":"Drugs of Today"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007698.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"A779","DOI":"10.1016\/S0016-5085(00)85260-9","article-title":"Beneficial effect of oral budesonide for distal ulcerative colitis: A comparative study of Budenfalk\u00ae 3 MG TID VS 9 MG OD","volume":"118","author":"Kolkman","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0300-2977(95)00090-9","article-title":"Budesonide in inflammatory bowel disease","volume":"48","author":"Lamers","year":"1996","journal-title":"Netherlands Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1016\/S0016-5085(12)63046-7","article-title":"Effect of budesonide MMX 6 mg on the hypothalamic-pituitary-adrenal (HPA) axis in patients with ulcerative colitis: Results from a phase III, 12 month safety and extended use study","volume":"142","author":"Lichtenstein","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/01.MIB.0000438826.05786.93","article-title":"Budesonide MMX versus placebo in patients with active, mild-to-moderate ulcerative colitis who were 5-ASA naive or previously treated with 5-ASA","volume":"19","author":"Lichtenstein","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/S0016-5085(13)60826-4","article-title":"Budesonide MMX 9 mg induces remission in mild-to-moderately active UC patients regardless of prior history of 5-ASA therapy","volume":"144","author":"Lichtenstein","year":"2013","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007698.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4321\/S1130-01082006000500007","article-title":"Budesonide for ulcerative colitis","volume":"98","author":"Mar\u00edn-Jim\u00e9nez","year":"2006","journal-title":"Revista Espa\u00f1ola de Enfermedades Digestivas"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1097\/01.MIB.0000438822.26871.fd","article-title":"Symptom resolution and clinical and endoscopic remission both resulted in improved quality of life in patients with ulcerative colitis","volume":"19","author":"Sandborn","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007698.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1016\/S0016-5085(13)60825-2","article-title":"Efficacy of budesonide MMX in reduction of symptoms in patients with mild-to-moderately active ulcerative colitis: A pooled analysis of the core I and core II studies","volume":"144","author":"Sandborn","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.14309\/00000434-201110002-01274","article-title":"Induction of clinical and endoscopic remission of mild to moderately active ulcerative colitis with budesonide MMX 9 MG: Analysis of pooled data from two phase 3 studies","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007698.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.13076","article-title":"Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies","volume":"41","author":"Sandborn","year":"2015","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eci.11.34","article-title":"Budesonide in the treatment of inflammatory bowel disease","volume":"7","author":"Silverman","year":"2011","journal-title":"Expert Review of Clinical Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007698.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/00054725-201112002-00066","article-title":"Induction of remission with oral budesonide MMXVR (9 mg) tablets in patients with mild to moderate, active ulcerative colitis: A multicenter, open-label efficacy and safety study","volume":"17","author":"Travis","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1873-9946(12)60182-2","article-title":"Induction of clinical and endoscopic remission with budesonide MMX in mild to moderately active ulcerative colitis: Pooled data from two phase 3 studies","volume":"6","author":"Travis","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD007698.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10350-004-6687-x","article-title":"Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis","volume":"46","author":"Bar-Meir","year":"2003","journal-title":"Diseases of the Colon and Rectum"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2005.05.003","article-title":"Molecular mechanisms and cellular effects of glucocorticosteroids","volume":"25","author":"Barnes","year":"2005","journal-title":"Immunology and allergy clinics of North America"},{"issue":"9573","key":"10.1002\/14651858.CD007698.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00005176-199605000-00006","article-title":"Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis","volume":"22","author":"Beattie","year":"1996","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.crohns.2007.12.001","article-title":"European evidence-based consensus on the management of ulcerative colitis: special situations","volume":"2","author":"Biancone","year":"2008","journal-title":"Journal of Crohn's and Colitis"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0037|cit37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007571.pub2","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis","author":"Bickston","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007698.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD007698.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/apt.12712","article-title":"Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis","volume":"39","author":"Danese","year":"2014","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/00365529209011158","article-title":"A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis","volume":"27","author":"Danielsson","year":"1992","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000338128","article-title":"Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?","volume":"30","author":"Cassan","year":"2012","journal-title":"Digestive Diseases"},{"issue":"10","key":"10.1002\/14651858.CD007698.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5","key":"10.1002\/14651858.CD007698.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/00054725-200409000-00012","article-title":"Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein","volume":"10","author":"Dilger","year":"2004","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"issue":"18","key":"10.1002\/14651858.CD007698.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. A population-based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy and inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1586\/17474124.2014.887437","article-title":"The role of budesonide-MMX in active ulcerative colitis","volume":"8","author":"Gionchetti","year":"2014","journal-title":"Expert Review of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bpg.2004.01.002","article-title":"Specificities of inflammatory bowel disease in childhood","volume":"18","author":"Griffiths","year":"2004","journal-title":"Best Practice and Research. Clinical Gastroenterology"},{"issue":"7650","key":"10.1002\/14651858.CD007698.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0051|cit51","first-page":"1188","article-title":"Mesalamine capsules for the treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12 Suppl 1","author":"Hanauer","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7414","key":"10.1002\/14651858.CD007698.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0054|cit54","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40265-015-0396-8","article-title":"Budesonide MMX(\u00ae): a review of its use in patients with mild to moderate ulcerative colitis","volume":"75","author":"Hoy","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"G7","DOI":"10.1152\/ajpgi.00079.2004","article-title":"Colorectal cancer in inflammatory bowel disease: the role of inflammation","volume":"287","author":"Itzkowitz","year":"2004","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0090-9556(25)06497-9","article-title":"Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver","volume":"23","author":"J\u00f6nsson","year":"1995","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3748\/wjg.v7.i2.175","article-title":"Historical origins of current IBD concepts","volume":"7","author":"Kirsner","year":"2001","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3748\/wjg.14.354","article-title":"Treatment of inflammatory bowel disease: a review of medical therapy","volume":"14","author":"Kozuch","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD007698.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/01.mib.0000235827.21778.d5","article-title":"Recent understanding of IBD pathogenesis: implications for future therapies","volume":"12","author":"Kucharzik","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002913.pub3","article-title":"Budesonide for maintenance of remission in Crohn's disease","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.MIB.0000217770.21261.ce","article-title":"Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study","volume":"12","author":"Lakatos","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005112.pub2","article-title":"Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","author":"Lawson","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007698.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","article-title":"Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis","volume":"29","author":"Lichtenstein","year":"2009","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"8706","key":"10.1002\/14651858.CD007698.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-B","article-title":"Preliminary report: cyclosporin in treatment of severe active ulcerative colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/gut.1.2.87","article-title":"Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis","volume":"1","author":"Lockhart-Mummery","year":"1960","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0025-7753(01)71716-2","article-title":"Budesonide in inflammatory bowel disease: a meta-analysis","volume":"116","author":"Nos","year":"2001","journal-title":"Medicina Cl\u00ednica"},{"issue":"7","key":"10.1002\/14651858.CD007698.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/00365527809182199","article-title":"A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis","volume":"13","author":"Powell-Tuck","year":"1978","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"6666","key":"10.1002\/14651858.CD007698.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalamine (5-aminosalicylic acid) versus sulphasalazine in active ulcerative colitis: a randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000296.pub4","article-title":"Budesonide for induction of remission in Crohn's disease","author":"Rezaie","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","author":"Riley","year":"1991","journal-title":"Gut"},{"issue":"23","key":"10.1002\/14651858.CD007698.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0076|cit76","first-page":"1079","article-title":"Modalities of corticosteroid therapy in inflammatory bowel disease","volume":"74","author":"Sabate","year":"1998","journal-title":"Semaine des H\u00f4pitaux de Paris"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00535-006-1995-7","article-title":"Inflammatory bowel disease: past, present, and future","volume":"42","author":"Sands","year":"2007","journal-title":"Journal of Gastroenterolgy"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD007698.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/0016-5085(86)90376-8","article-title":"Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-graunlocyte excretion","volume":"90","author":"Saverymuttu","year":"1986","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1002\/14651858.CD007698.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007698.pub3-BIB0080|cit80","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0081|cit81","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD007698.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1517\/17425250903124355","article-title":"Budesonide for Crohn's disease","volume":"5","author":"Seow","year":"2009","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007698.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007698.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub3","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"s1","key":"10.1002\/14651858.CD007698.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2036.2006.03070.x","article-title":"Review article: induction therapy for patients with active ulcerative colitis","volume":"24","author":"Travis","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"61","author":"Travis","year":"2012","journal-title":"Gut"},{"issue":"4947","key":"10.1002\/14651858.CD007698.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD007698.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007698.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of the phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Limbergen","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD007698.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"issue":"7152","key":"10.1002\/14651858.CD007698.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"issue":"10","key":"10.1002\/14651858.CD007698.pub3-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007698.pub2","article-title":"Oral budesonide for induction of remission in ulcerative colitis","author":"Sherlock","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007698.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:24:08Z","timestamp":1748665448000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007698.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,26]]},"references-count":93,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007698.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,26]]}}}